Quest Diagnostics Incorporated (DGX) Stock Price: $206.24+3.13 (+1.54%)
At close: Jun 25, 2026, 4:00 PM ET
The closing share price for Quest Diagnostics Incorporated (DGX) stock was $206.24 for Thursday, June 25, 2026, up 1.54% on the day.
Longer view (total return, dividends reinvested): past 12 months +17.5% · 3-year avg +15.6%/yr · 5-year avg +11.9%/yr
DGX Price Chart
DGX Key Metrics
See All MetricsLAST CLOSE PRICE
$206.24
52-WEEK RANGE
$164.65 - $213.50
BETA
0.59
% FROM 52W HIGH
-3.40%
MARKET CAP
$22.83B
DIVIDEND YIELD
1.58%
PE RATIO
trailing TTM
22.79
PE RATIO (FWD)
next-FY estimate
17.67
P/B RATIO
3.14
DEBT / EQUITY
0.96
REVENUE TTM
$11.28B
NET INCOME TTM
$1.02B
NET PROFIT MARGIN TTM
9.08%
TTM TOTAL RETURN
+17.53%
3Y TOTAL RETURN
+15.63%
5Y TOTAL RETURN
+11.90%
DGX Earnings Preview
Next Earnings Date
Jul 23, 2026
27 days away
EPS Estimate
2.81
Revenue Est.
$2.98B
Last Quarter Results
EPS
$2.50
vs Estimate
$2.37
Revenue
$2.90B
vs Estimate
$2.83B
DGX Analyst Ratings
Consensus Rating
Based on 16 analysts
Average Price Target
$223.44
+8.3% upside
Low
$184.00
Current
$206.24
High
$245.00
DGX Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $2.67 | $2.72 | $2.78 | 4 |
| Q2 2027 | $2.98 | $3.03 | $3.10 | 5 |
| Q3 2027 | $2.96 | $3.02 | $3.08 | 8 |
| Q4 2027 | $2.79 | $2.84 | $2.90 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $11.43 | $11.67 | $12.05 | 12 |
| FY 2028 | $12.02 | $12.73 | $13.52 | 7 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $2.97B | $3.01B | $3.06B | 5 |
| Q2 2027 | $3.04B | $3.08B | $3.14B | 5 |
| Q3 2027 | $3.07B | $3.11B | $3.16B | 5 |
| Q4 2027 | $3.06B | $3.10B | $3.15B | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $12.20B | $12.39B | $12.61B | 14 |
| FY 2028 | $12.90B | $12.93B | $12.95B | 11 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareDGX Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DGX | $22.83B | $206.24 | +1.54% | +17.53% | +11.90% | +12.28% | — |
| 2BNTX | $22.76B | $90.00 | -0.23% | -14.13% | -16.89% | N/A | vs DGX |
| 3UTHR | $23.07B | $543.39 | -1.18% | +90.10% | +24.73% | +18.19% | vs DGX |
| 4MRNA | $23.71B | $59.75 | -1.11% | +122.57% | -22.95% | N/A | vs DGX |
| 5LH | $21.83B | $266.20 | +0.38% | +3.99% | +4.07% | +9.67% | vs DGX |
| 6INCY | $21.48B | $107.53 | -0.86% | +59.24% | +4.37% | +3.40% | vs DGX |
DGX Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis